Valvular & structural heart diseaseRandomised controlled trial
Tricuspid-Valve Intervention in Heart Failure
- Randomised controlled trial
- 2:1 randomisation
- hierarchical primary end point (win ratio)
Authors' conclusion
Among patients with symptomatic severe tricuspid regurgitation, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone with respect to a hierarchical composite of death from any cause, hospitalization for heart failure, and quality-of-life improvement at 1 year and was also associated with a lower risk of a composite of death from any cause or hospitalization for heart failure through 3 years.
Study context
- Population
- Patients with symptomatic severe tricuspid regurgitation and increased risk of future HF events
- Participants
- 360 patients
- Comparison
- Tricuspid repair vs Medical therapy
- Tricuspid repairn = 237
- Medical therapyn = 123reference
- Primary endpoint
- First: hierarchical composite of all-cause death, HF hospitalization and quality-of-life improvement (win ratio); second (tested if first significant): all-cause death or HF hospitalization
- Follow-up
- 1 year (first); through 3 years (second)
Primary result
As reported in the abstract
Tricuspid repair vs Medical therapyWin ratio (95% CI)P value
first primary end point at 1 year
2.42(1.76–3.33)
P < 0.001Tricuspid repair vs Medical therapyHazard ratio (95% CI)P value
second primary end point: all-cause death or HF hospitalization through 3 years
0.40(0.29–0.55)
P < 0.001Safety
| Outcome | Tricuspid repair | Medical therapy |
|---|---|---|
| Major adverse events within 30 days | 5.9% | Not reported in the abstract |
Original publication
Tricuspid-Valve Intervention in Heart Failure. N Engl J Med. Published 30 August 2026. doi:10.1056/nejmoa2606934
Summarised from the published abstract; every number is checked against it